High Sustained Virologic Response Rates in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection Receiving ABT-450/r/Ombitasvir plus Dasabuvir Plus Ribavirin

被引：0

作者：

Mantry, Parvez S. ^{[1
]}

Kwo, Paul Y. ^{[2
]}

Coakley, Eoin ^{[3
]}

Te, Helen S. ^{[4
]}

Vargas, Hugo E. ^{[5
]}

Brown, Robert S. ^{[6
]}

Gordon, Fredric D. ^{[7
]}

Levitsky, Josh ^{[8
]}

Terrault, Norah ^{[9
]}

Burton, James R. ^{[10
]}

Xie, Wangang ^{[3
]}

Setze, Carolyn ^{[3
]}

Badri, Prajakta ^{[3
]}

Vilchez, Regis A. ^{[3
]}

Forns, Xavier ^{[11
,12
]}

机构：

[1] Liver Inst Methodist Dallas, Dallas, TX USA

[2] Indiana Univ, Indianapolis, IN 46204 USA

[3] AbbVie Inc, N Chicago, IL USA

[4] Univ Chicago Med, Chicago, IL USA

[5] Mayo Clin, Mayo Clinic, AZ 5 USA

[6] Columbia Univ, Ctr Liver Dis & Transplantat, Med Ctr, New York, NY USA

[7] Lahey Hosp & Med Ctr, Burlington, MA USA

[8] Northwestern Univ, Comprehens Transplant Ctr, Chicago, IL 60611 USA

[9] Univ Calif San Francisco, San Francisco, CA 94143 USA

[10] Univ Colorado, Denver, CO 80202 USA

[11] IDIBAPS, Hosp Clin, Liver Unit, Barcelona, Spain

[12] CIBEREHD, Barcelona, Spain

来源：

HEPATOLOGY | 2014年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

198

引用

页码：298A / 299A

页数：2

共 50 条

[31] REDUCTION IN ANNUAL MEDICAL COSTS WITH EARLY TREATMENT OF HCV USING ABBVIE 3D (ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR) plus /- RIBAVIRIN IN THE UNITED STATES
Misurski, D. A.
Johnson, S. J.
Samp, J. C.
Marx, S. E.
Juday, T. R.
Virabhak, S.
Parise, H.
Saab, S.
JOURNAL OF HEPATOLOGY, 2015, 62 : S642 - S642
[32] COST-EFFECTIVENESS OF TREATING DIFFERENT STAGES OF GENOTYPE 1 HEPATITIS C VIRUS (HCV) WITH ABBVIE 3D (ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR) plus /- RIBAVIRIN COMPARED TO NO TREATMENT IN THE UNITED STATES
Johnson, S. J.
Misurski, D. A.
Juday, T. R.
Samp, J. C.
Marx, S. E.
Parise, H.
Virabhak, S.
Saab, S.
JOURNAL OF HEPATOLOGY, 2015, 62 : S641 - S642
[33] TURQUOISE-I: 94% SVR12 in HCV/HIV-1 Coinfected Patients Treated with ABT-450/r/Ombitasvir, Dasabuvir and Ribavirin
Wyles, David L.
Sulkowski, Mark S.
Eron, Joseph J.
Trinh, Roger
Lalezari, Jay
Slim, Jihad
Gathe, Joseph C.
Wang, Chia C.
Elion, Richard
Bredeek, Fritz
Brennan, Robert O.
Blick, Gary
Khatri, Amit
Gibbons, Krystal
Hu, Yiran
Fredrick, Linda
Pilot-Matias, Tami
Da Silva-Tillmann, Barbara
McGovern, Barbara H.
Campbell, Andrew L.
Podsadecki, Thomas
HEPATOLOGY, 2014, 60 : 1136A - 1137A
[34] Predictors of Sustained Virologic Response in 21,242 Genotype 1 Patients Treated with Ledipasvir/Sofosbuvir Ribavirin or Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir Ribavirin in Routine Medical Practice
Backus, Lisa I.
Belperio, Pamela S.
Shahoumian, Troy A.
Loomis, Timothy P.
Mole, Larry A.
HEPATOLOGY, 2016, 64 : 1000A - 1000A
[35] Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/ plus Dasabuvir plus /-Ribavirin (OBV/PTV/r/ plus DSV plus /-RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study
Tronina, Olga
Durlik, Magdalena
Wawrzynowicz-Syczewska, Marta
Buivydiene, Arida
Katzarov, Krum
Kupcinskas, Limas
Tolmane, Ieva
Karpinska, Ewa
Pisula, Arkadiusz
Karwowska, Kornelia Magdalena
Bolewska, Beata
Jablkowski, Maciej
Rostkowska, Karolina
Jakutiene, Jolita
Simonova, Marieta
Flisiak, Robert
ANNALS OF TRANSPLANTATION, 2017, 22 : 199 - 207
[36] A Meta-Analysis of the Association Between Pre-Treatment Variables and SVR Amongst Genotype 1 Patients Treated with ABT-450/r-Ombitasvir and Dasabuvir (VIEKIRA PAK™) plus Ribavirin for 12 Weeks
Botwin, Gregory J.
Morgan, Timothy R.
HEPATOLOGY, 2015, 62 : 766A - 766A
[37] Interferon-Free Regimens of Ombitasvir and ABT-450/r With or Without Ribavirin in Patients With HCV Genotype 4 Infection: PEARL-I Study Results
Pol, Stanislas
Reddy, K. Rajender
Baykal, Tolga
Hezode, Christophe
Hassanein, Tarek
Marcellin, Patrick
Berenguer, Marina
Fleischer-Stepniewska, Katarzyna M.
Hall, Coleen
Collins, Christine
Vilchez, Regis A.
HEPATOLOGY, 2014, 60 : 1129A - 1130A
[38] CHILDREN WITH HCV INFECTION SHOW HIGH SUSTAINED VIROLOGIC RESPONSE RATES ON PEGINTERFERON ALFA-2B PLUS RIBAVIRIN TREATMENT
Wirth, Stefan
Ribes-Koninckx, Carmen
Bortolotti, Flavia
Zancan, Lucia
Jara, Paloma
Shelton, Mark M.
Kerkar, Nanda
Galoppo, Cristina
Rodriguez-Baez, Norberto
Ciocca, Mirta
Lachaux, Alain
Lacaille, Florence
Lang, Thomas
Kullmer, Ulrike
Huber, Wolf Dietrich
Gonzalez, Teresita
Pollack, Henry
Alonso, Estella M.
Broue, Pierre
Ramakrishna, Jyoti
Neigut, Deborah
Del Valle-Segarra, Antonio I.
Hunter, Bessie A.
Brass, Clifford A.
Noviello, Stephanie
Sniukiene, Vilma
Harvey, Joann
Albrecht, Janice K.
HEPATOLOGY, 2008, 48 (04) : 392A - 393A
[39] Time to Viral Suppression is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
Sulkowski, Mark S.
Fried, Michael W.
Ozaras, Resat
Isakov, Vasily
Wyles, David L.
Ferenci, Peter
Feld, Jordan J.
Calinas, Filipe
Gschwantler, Michael
King, Martin
Baykal, Tolga
Gane, Edward J.
HEPATOLOGY, 2014, 60 : 1144A - 1145A
[40] Safety of Ribavirin-containing Regimens of ABT-450/r, ABT-333, and ABT-267 for the Treatment of HCV Genotype 1 Infection and Efficacy in Subjects with Ribavirin Dose Reductions
Cohen, Daniel E.
Xie, Wangang
Larsen, Lois
Marincic, Christal
Knauss-Townsend, Mary
Khatri, Amit
Podsadecki, Thomas
Bernstein, Barry
HEPATOLOGY, 2013, 58 : 754A - 755A

← 1 2 3 4 5 →